


LISTING OF CLAIMS

CLAIMS 1-14 (CANCELED) :

15. (NEW) A compound of formula (I),



5

wherein :

10

- R₁ and R₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R₃ represents halogen, alkoxy, an optionally substituted aryl group or NR'₁R'₂ wherein R'₁ and R'₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R₄ represents hydrogen or NR''₁R''₂ wherein R''₁ and R''₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

15

its enantiomers, diastereoisomers, tautomers and addition salts thereof with a pharmaceutically acceptable acid or base,


it being understood that :

20

- the term "alkyl" denotes linear or branched hydrocarbon chain having from 1 to 8 carbon atoms,
- the term "alkoxy" denotes alkyl-oxy wherein the alkyl chain is linear or branched and has from 1 to 8 carbon atoms,

- the term "aryl" denotes phenyl or naphthyl,
- the term "heterocycle" denotes a mono- or bi-cyclic system which has from 5 to 11 carbon atoms and which may contain, in addition to the nitrogen atom to which R_1R_2 , $R'_1R'_2$ or $R''_1R''_2$ are bonded, one or two further hetero atoms selected from oxygen, sulphur and nitrogen, it being possible for the heterocyclic system to be substituted by one, two or three alkyl groups,
- the term "substituted" associated with aryl indicates that the phenyl or naphthyl group is substituted by one, two or three identical or different groups selected from halogen, alkyl, alkoxy, polyhaloalkyl and hydroxy,
- "polyhaloalkyl" denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms.

16. (NEW) A compound of Claim 15, which is represented by formula (I'),



17. (NEW) A compound of Claim 15, wherein NR_1R_2 represents NH_2 , di-*n*-propylamine or morpholine.

18. (NEW) A compound of Claim 16, wherein NR_1R_2 represents NH_2 , di-*n*-propylamine or morpholine.

19. (NEW) A compound of Claim 15, wherein R_3 represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

20. (NEW) A compound of Claim 16, wherein R₃ represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

21. (NEW) A compound of Claim 16, wherein R₄ represents hydrogen, morpholine or azepine.

5 22. (NEW) A compound of Claim 16, wherein R₄ represents hydrogen, morpholine or azepine.

23. (NEW) A compound of Claim 15 which is selected from :

2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azocanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

10 8-((4 α ,8 α)-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-((4 α ,8 α)-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

6,8-di(1-azepanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

15 8-(1-azepanyl)-2-(dipropylamino)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azepanyl)-2,6-di(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-[(3 α ,5 β)-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 α ,5 β)-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

20 8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]-2-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

25 2-amino-8-(1-azepanyl)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-chloro-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-(dipropylamino)-8-(1-pyrrolidinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

and 8-(3,4-dimethoxyphenyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one.

arthrosis, and arterial hypertension, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 15 which is effective for alleviation of the condition.

5 **25. (NEW)** A method for treating a living animal body, including a human, afflicted with a condition selected from non-insulin-dependent, type II diabetes and cardiovascular complications thereof, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 15 which is effective for alleviation of the condition.

10 **26. (NEW)** A method for treating a living animal body, including a human, afflicted with cancer, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 15 which is effective for alleviation of cancer.

15 **27. (NEW)** A method for treating a living animal body, including a human, afflicted with arthrosis, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 15 which is effective for alleviation of arthrosis.

28. (NEW) A method for treating a living animal body, including a human, afflicted with arterial hypertension, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 15 which is effective for alleviation of arterial hypertension.